transmembrane protein 11Genealiases: C17orf35 · PM1 · PMI
Q-omics provides the consensus-scored TMEM11 profile across patient tissues and cancer cell-line models. TMEM11 expression is associated with patient survival in 21 of 34 cancer types, with the highest sampling consensus in ACC. Among the 18 cancer types available for tumor–normal comparison, TMEM11 is differentially expressed in 16, with the highest sampling consensus in KIRC. Additionally, TMEM11 protein abundance shows 20,922 significant protein co-abundance associations, with the highest sampling consensus in GBM. Together, these results highlight ACC, KIRC, and GBM as cancer lineages where TMEM11 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for TMEM11 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes TMEM11 survival associations across molecular data types. TMEM11 RNA expression shows survival associations in the most cancer types (21), followed by mutation status (4) and mass-spec protein abundance (5). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible TMEM11 RNA expression–survival associations across cancer types. High TMEM11 expression shows unfavorable associations in ACC, LUAD, KICH, UVM, LIHC and BLCA. The ACC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify ACC as the clearest survival context for TMEM11 RNA expression.
This table summarizes TMEM11 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 16, while mass-spec protein shows differences in 5. The strongest signals are observed in KIRC for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for TMEM11. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. TMEM11 shows lower tumor expression in KICH and higher tumor expression in KIRC, HNSC, LIHC, KIRP and BLCA. The KIRC box plot shows higher TMEM11 RNA expression in tumor versus normal tissue (log2 FC = +0.538, t-test p < 0.001).
This table shows molecular features associated with TMEM11 in patient tissues and cancer cell lines. In patient samples, TMEM11 shows the broadest associations at the RNA and protein expression levels, with GBM recurring as the lineage with the largest associated feature set. In cancer cell lines, TMEM11 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in SOFT_TISSUE, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Lymphoma and BLOOD_Leukemia.
